entertainment -WSS

entertainment

author：knowledge 2025-09-28 16:34:52 - browse：85

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： ASCO: AstraZeneca says CAR

WSS

See how much Covid

Medicare to cover more brain scans related to Alzheimer’s drugs

At ASCO, AstraZeneca reports strong data for breast cancer drug

Ultragenyx gene therapy for rare liver ailment succeeds in late

Takeaways from AdvaMed, the largest medical devices conference

STAT Readout: Today's biotech news includes Sana and Amylyx

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Drug repurposing or repositioning? The language matters

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Kaiser's Risant Health gobbled up Geisinger. Who is next?

The high cost of giving birth even with insurance

Letters to First Opinion on caregivers, digital health, and more

Virginia high school admissions case could be legal follow

See how much Covid

What does generative AI mean for health care? We asked experts

What's changing in Medicare's open enrollment this year?

focus

A revolution in caring for preterm infants

With trial win, GSK could get blood cancer drug back on market

With trial win, GSK could get blood cancer drug back on market

Shifting the focus from loneliness to social health

Intellia reports positive results for its CRISPR

Cancer cells are shown to suck energy source from immune cells

focus

focus

explore

focus